PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

London based deal experts are the exclusive advisors for this and the ongoing partnering efforts for WM-A1-3389.

London, UK, 08 February 2023

PharmaVentures is pleased to announce that it acted as exclusive advisor for Wellmarker Bio Co., Ltd (WMBIO) on its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.

Adrian Dawkes, Managing Director at PharmaVentures, said “We are pleased to have assisted WMBIO in establishing this collaboration with MSD. We have been working with Wellmarker Bio for some time now and it is gratifying to see this collaboration come to fruition. We look forward to helping Wellmarker with more partnerships as their pipeline progresses.”

Dong-Hoon Jin, CEO of Wellmarker Bio, said “This clinical trial collaboration with MSD holds great significance for WMBIO as it allows us to evaluate a first-in-class drug with a novel mechanism in combination with KEYTRUDA. We engaged PharmaVentures as our advisors for this collaboration and continue to work with them in partnering for WM-A1-3389.”

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to be supporting our client WMBIO in their collaboration with MSD. PharmaVentures has an extensive industry network and the specialist expertise to connect the Korean and Western Biopharma industries and vice versa, enabling them to collaborate through licensing and M&A deals.”

 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

For press enquiries, please contact:

Lisa Holloway

Senior Marketing Manager

PharmaVentures Ltd

+44 (0) 1865 332700